Friday 6 November 2026 Export ADTX’s income statement to Excel — free account

Aditxt, Inc.

ADTX Healthcare Biotechnology

Aditxt, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3,200.00, down 97.6% from fiscal 2024.

Revenue: +1,120.0%
EPS: +99.6%
Free cash flow: +60.8%

Quarter to March 2026, against a year earlier

Insider buying

0.00 0.00 NaN

Follow ADTX

Alert me

Market cap: $4.4M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: 4/9
Altman Z: −22.29
Beneish M: n/a
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Bought, $m 0.36

Sold, $m 0.34

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	1	—	6	—	—	—	—	—
Sell	1	—	—	—	2	—	9	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Size

Market Cap 4.39

Revenue ttm 0.01

Net income ttm (53.02)

Free cash flow ttm (18.59)

Net debt Q (0.27)

Valuation

P/E 0.00

Forward P/E —

Price / sales 0.00

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.00

Financial health

Current ratio Q 0.06

Debt / equity Q 0.00

Interest coverage Q (160.96)

Growth

Revenue growth Q +1,120.00%

Operating income growth Q +22.22%

EPS, this year +73.23%

EPS, next year A −0.78%

Revenue, next year A —

EPS, past 5 yrs —

EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

EV/Sales against its own 10 years 39.83%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	0	1	3	0
Receivables	6	1	—	0
Inventory	1	0	0	0
Other	—	—	—	—
	7	2	4	1

	2023	2024	2025	Q'26
Payables	9	13	8	8
ST’ Debt	—	—	—	—
Other	0	2	2	1
	26	23	12	13

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	(84.92%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(18.52%)	(8.77%)

Earnings Trends EPS, adjusted, against the consensus

Mar 2024 Estimate −818,181,760.00 Actual −2,245,700,096.00

−59,439,918,035.20 −42,872,905,609.60 −26,305,893,184.00 −9,738,880,758.40 6,828,131,667.20

Sep 2022 Miss −27,223,582,720.00

Jun 2023 Beat +19,361,177,600.00

Sep 2023 Miss −10,511,055,616.00

Mar 2024 Miss −1,427,518,336.00

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Sep 2022	−24,570,021,888.00	−51,793,604,608.00	Miss by 27,223,582,720.00
Jun 2023	−28,402,946,048.00	−9,041,768,448.00	Beat by 19,361,177,600.00
Sep 2023	−1,471,744,256.00	−11,982,799,872.00	Miss by 10,511,055,616.00
Mar 2024	−818,181,760.00	−2,245,700,096.00	Miss by 1,427,518,336.00

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(790.49)	—	—	—	—
’25	(199.51k)	(84.21k)	(118.66k)	(1.17k)	(31.18k)
’24	(1000.00m)	(25.56m)	(682.25m)	1.00b	(74.75m)
’23	(52.46)	(36.79)	(1.92k)	(658.26m)	(659.95m)
’22	(6.80)	(6.42)	(210.93)	(372.15)	(596.30)
’21	(0.46)	(0.42)	(28.08)	(92.49)	(121.45)
’20	(0.30)	(0.14)	(0.37)	(0.52)	(1.33)

Fiscal quarters ending in the months shown.

Revenue $m

	Jun	Sep	Dec	Year
’26	—	—	—	—
’25	0	0	0	0
’24	0	0	0	0
’23	0	0	0	1
’22	0	0	0	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(5)	—	—	—	—
’25	(12)	(2)	(2)	(9)	(26)
’24	(6)	(2)	(2)	(6)	(17)
’23	(4)	(3)	(8)	(4)	(19)
’22	(5)	(3)	(8)	(7)	(22)
’21	(4)	(5)	(5)	(9)	(22)
’20	0	0	(4)	(3)	(7)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(5)	—	—	—	—
’25	(12)	(2)	(2)	(9)	(26)
’24	(6)	(2)	(2)	(6)	(17)
’23	(4)	(3)	(8)	(4)	(19)
’22	(5)	(3)	(8)	(7)	(23)
’21	(5)	(5)	(5)	(9)	(23)
’20	0	0	(4)	(3)	(7)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Mar ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	—	—	—	—	—	0	1	1	0	0	0		(58.2%)	—	—	—	—
	Gross margin, %	—	—	—	—	0.00	25.81	17.88	(17.31)	(368.28)	9.38	20.28		+9.4 pt	Powerpack Aditxt, Inc.’s next three years, line by line See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	—	0	(6)	(6)	(9)	(46)	(28)	(32)	(35)	(43)	(53)		+94.0%
	EBT margin, %	—	0.00	0.00	0.00	0.00	(44,163.24)	(2,961.33)	(5,020.23)	(26,134.40)	(1,337,093.75)	(370,796.50)		(1,337,093.7) pt
	Net income	—	0	(6)	(6)	(9)	(46)	(28)	(32)	(35)	(43)	(53)		n/m
Per share, $
Per share, $	Revenue	—	0.00	0.00	0.00	0.00	0.28	20.12	13,034,343.43	248,194.11	2.31	0.71		n/m
	Earnings	—	(2.06)	(2,199.80)	(1.52)	(1.33)	(121.45)	(596.30)	(659,949,850.00)	(74,749,744.00)	(31,184.59)	(204,820.48)		+233.0%
	Cash flow	—	0.00	(148.58)	(0.12)	(1.05)	(58.35)	(482.59)	(387,953,535.35)	(31,046,675.31)	(18,567.42)	(918.50)		n/m
	Capex	—	0.00	0.00	0.00	(0.02)	(2.66)	(7.91)	(290,909.09)	0.00	(9.90)	(1.65)		n/m
	Free cash flow	—	0.00	(148.58)	(0.12)	(1.07)	(61.01)	(490.50)	(388,244,444.44)	(31,046,675.31)	(18,577.32)	(920.15)		n/m
	Book value	—	(0.58)	(591.04)	(0.74)	1.60	26.67	112.20	324,177,777.78	2,021,485.46	2,857.71	(1,741.31)		n/m
	Shares, m	—	0	0	4	7	0	0	0	0	0	0		(41.7%)
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00		0.0
	P/S	—	—	—	—	—	0.00	19,164,606.36	0.00	0.00	303.30	0.00		3,832,981.9
	P/B	—	—	—	—	—	4,907,185.85	3,436,988.45	0.00	0.00	0.24	0.00		1,668,834.9
	EV/Sales	—	—	—	—	—	0.00	19,164,604.81	1.89	3.61	(303.83)	73.26		3,832,861.3
	EV/FCF	—	—	—	—	—	(2,144,727.64)	(786,234.58)	(0.06)	(0.03)	0.04	(0.06)		(586,192.5)
Cash, $m
Cash, $m	Operating cash flow	—	—	0	0	(7)	(22)	(22)	(19)	(17)	(26)	(19)		+82.1%
	Capex	—	—	—	—	0	(1)	0	0	—	0	0		(39.6%)
	Free cash flow	—	—	0	0	(7)	(23)	(23)	(19)	(17)	(26)	(19)		+82.2%
Balance, $m
Balance, $m	Working capital	—	0	(2)	(3)	10	6	1	(19)	(21)	(8)	(12)		+98.5%
	Net debt	—	0	0	0	(11)	(8)	(3)	0	(1)	(3)	0		+83.4%
	Shareholders’ equity	—	0	(2)	(3)	11	10	5	16	1	4	(35)		n/m
Returns, %
Returns, %	ROA	—	(302.77)	(9,834.40)	(4,872.66)	(138.41)	(310.94)	(202.11)	(118.24)	(105.19)	(177.15)	(236.38)		+125.6 pt
	ROIC	—	0.00	0.00	0.00	(1,085.79)	(1,135.24)	(653.28)	(102.13)	(6,739.48)	(1,619.88)	0.00		(1,619.9) pt
	ROE	—	26.68	712.66	265.57	(224.26)	(436.66)	(359.88)	(307.73)	(470.92)	(1,708.68)	549.59		(1,735.4) pt
People
People	Employees	—	—	—	—	43	58	61	47	26	26	—		(9.6%)
	Revenue/emp, $m	—	—	—	—	0.00	0.00	0.02	0.01	0.01	0.00	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NIKI Niki BioSolutions, Inc.	$4.7M	— (loss-making)	31.9×	−32.36% (below 0%: shrinking)	+69.51% (above 0%: growing)	+58.14% (above 0%: growing)	(154.22%)	0.00%	Compare
SKYE Skye Bioscience, Inc.	$4.6M	— (loss-making)	—	−34.71% (below 0%: shrinking)	n/m	+34.84% (above 0%: growing)	72.71%	0.00%	Compare
ADTX Aditxt, Inc.	$4.4M	— (loss-making)	—	+1,120.00% (above 0%: growing)	n/m	+60.82% (above 0%: growing)	23.77%	(35,753.28%)
AZTR Azitra, Inc.	$4.4M	1.3×	— (loss-making)	−93.38% (below 0%: shrinking)	n/m	−19.55% (below 0%: shrinking)	100.00%	0.00%	Compare
XBIO Xenetic Biosciences, Inc.	$4.4M	— (loss-making)	— (loss-making)	+11.99% (above 0%: growing)	n/m	−128.11% (below 0%: shrinking)	100.00%	(147.09%)	Compare
OSRH OSR Health, Inc.	$4.1M	— (loss-making)	—	−72.20% (below 0%: shrinking)	n/m	−398.76% (below 0%: shrinking)	27.43%	(960.69%)	Compare
NCNA NuCana PLC Sponsored ADR	$4.0M	— (loss-making)	—	—	n/m	+55.66% (above 0%: growing)	0.00%	0.00%	Compare
PMCB Nuvilex Inc.	$4.0M	— (loss-making)	—	−103.94% (below 0%: shrinking)	n/m	+60.84% (above 0%: growing)	100.00%	0.00%	Compare
CELZ Creative Medical Technology Holdings, Inc.	$4.0M	— (loss-making)	— (loss-making)	0.00%	n/m	−27.05% (below 0%: shrinking)	66.67%	0.00%	Compare
Median of peers	$4.2M	—	—	−34.71%	—	+7.64%	69.69%	0.00%

All 621 Biotechnology stocks →

Aditxt, Inc. (ADTX) Latest News

25 Jun

Impact 4 · 4:06 AM · Stocktwits

ADTX Stock Loses Nasdaq Listing After Seven Reverse Splits Fail To Restore Compliance: Why Is Retail Still Bullish?

23 Jun

Impact 4 · 1:29 AM · Stocktwits

ADTX Stock Surges 40% Overnight: New 10% Holder Emerges After Aditxt’s Ignite Proteomics SPAC Deal

10 Jun

Impact 4 · 7:09 AM · pharmaceutical-technology.com

Aditxt and Ignite announce merger plans with strategic partner

9 Jun

Impact 4 · 12:47 PM · Stocktwits

Why Is ADTX Stock In Spotlight Today?

Impact 4 · 7:45 AM · Business Wire

Aditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 Million

Impact 4 · 8:15 AM · Business Wire

Evofem Biosciences’ CEO Saundra Pelletier Joins Aditxt Board of Directors

8 Jun

Impact 4 · 8:15 AM · Business Wire

Ignite Proteomics Announces Prospective 10,000-Patient Oncology Registry to Evaluate Functional Proteomics in Cancer Therapy Selection

1 Jun

Impact 3 · 8:15 AM · Business Wire

Aditxt, Inc. Appoints Jeffrey M. Busch as Interim Chief Executive Officer; Founder and Former CEO of $1B NYSE Enterprise Which Delivered ~8.5% Dividends to Shareholders

14 May

Impact 3 · 8:15 AM · Business Wire

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-27 Reverse Stock Split Effective at the Open of Trading on May 18, 2026

20 Apr

Impact 4 · 8:15 AM

Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics’ RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients

13 Mar

Impact 4 · 8:15 AM · Business Wire

Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection

5 Mar

Impact 3 · 8:30 AM · Business Wire

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026

17 Dec

Impact 3 · 10:30 AM · Associated Press Finance

BC-Most Active Stocks

31 Oct

Impact 3 · 10:30 AM

BC-Most Active Stocks

29 Oct

Impact 3 · 4:30 PM · Business Wire

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025

28 Oct

Impact 3 · 10:30 AM · Associated Press Finance

BC-Most Active Stocks

27 Oct

Impact 4 · 8:30 AM · Business Wire

Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market

24 Oct

Impact 3 · 10:30 AM · Associated Press Finance

BC-Most Active Stocks

9 Sep

Impact 4 · 9:28 AM

Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting

25 Aug

Impact 4 · 9:15 AM

Aditxt’s Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030

14 Aug

Impact 3 · 8:46 AM · PR Newswire

Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update

29 Jul

Impact 4 · 9:00 AM · Business Wire

Aditxt’s Subsidiary, Pearsanta, Inc. Engages Spartan Capital as Lead Underwriter for its Planned IPO Intending to Drive Clinical Validation and Commercial Rollout of Its Mitomic™ Platform Technology for Early Detection of Cancers and Other Diseases

24 Jul

Impact 4 · 8:15 AM

Aditxt’s Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic® Ovarian Test

15 Jul

Impact 4 · 9:12 AM · PR Newswire

Phexxi -- A Non‑Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy

26 Jun

Impact 4 · 8:15 AM · Business Wire

Aditxt to Present at Wall Street Reporter’s NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET

5 Jun

Impact 3 · 8:15 AM

Saundra Pelletier, Evofem Biosciences’ CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6

19 May

Impact 3 · 8:00 AM

Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.

Impact 3 · 8:00 AM · Business Wire

Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics

2 May

Impact 4 · 9:00 AM

Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™

17 Apr

Impact 3 · 8:15 AM

Dr. Charles Howe of the Mayo Clinic’s Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt’s Subsidiary Adimune™

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Aditxt, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Aditxt, Inc. (ADTX) Latest News

25 Jun

23 Jun

10 Jun

9 Jun

8 Jun

1 Jun

14 May

20 Apr

13 Mar

5 Mar

17 Dec

31 Oct

29 Oct

28 Oct

27 Oct

24 Oct

9 Sep

25 Aug

14 Aug

29 Jul

24 Jul

15 Jul

26 Jun

5 Jun

19 May

2 May

17 Apr

Stockrow Weekly